Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 1863-1867

  Pea, Federico ^a   Furlanut, Mario ^a   Negri, Camilla ^a   Pavan, Federica ^a   Crapis, Massimo ^a   Cristini, Francesco ^a   Viale, Pierluigi ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORRELATION ANALYSIS; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; NOMOGRAM; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; STEADY STATE; VALIDITY;

AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; CREATININE; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; NOMOGRAMS; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 66149108761     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01149-08     Document Type: Article

References (37)

1. Alos, J. I., A. Garcia-Canas, P. Garcia-Hierro, and F. Rodriguez-Salvanes. 2008. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J. Antimicrob. Chemother. 62:773-775.
2. American Thoracic Society and Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator- associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
3. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
4. Dellinger, R. P., M. M. Levy, J. M. Carlet, J. Bion, M. M. Parker, R. Jaeschke, K. Reinhart, D. C. Angus, C. Brun-Buisson, R. Beale, T. Calandra, J. F. Dhainaut, H. Gerlach, M. Harvey, J. J. Marini, J. Marshall, M. Ranieri, G. Ramsay, J. Sevransky, B. T. Thompson, S. Townsend, J. S. Vender, J. L. Zimmerman, and J. L. Vincent. 2008. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 34:17-60.
5. Deresinski, S. 2007. Counterpoint: vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence. Clin. Infect. Dis. 44:1543-1548. (Pubitemid 46871499)
6. Drew, R. H., I. Lu, M. Joyce, D. K. J. Benjamin, and V. G. Fowler. 2004. Lack of relationship between predicted area under the time-concentration curve/minimum inhibitory concentration and outcome in vancomycin-treated patients with Staphylococcus aureus bacteremia, abstr. A-1493. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
7. Gonzalez-Ruiz, A., and J. Richardson. 2008. Are glycopeptides still appropriate and convenient for empiric use? J. Chemother. 20:531-541.
8. Gould, I. M. 2008. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int. J. Antimicrob. Agents 31(Suppl. 2):1-9.
9. Herrera-Gutierrez, M. E., G. Seller-Perez, E. Banderas-Bravo, J. Munoz- Bono, M. Lebron-Gallardo, and J. F. Fernandez-Ortega. 2007. Replacement of 24-h creatinine clearance by 2-h creatinine clearance in intensive care unit patients: a single-center study. Intensive Care Med. 33:1900-1906. (Pubitemid 47632255)
10. Hidayat, L. K., D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138-2144. (Pubitemid 44631403)
11. Hoste, E. A., J. Damen, R. C. Vanholder, N. H. Lameire, J. R. Delanghe, K. Van den Hauwe, and F. A. Colardyn. 2005. Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrol. Dial. Transplant. 20:747-753. (Pubitemid 40520652)
12. Ingram, P. R., D. C. Lye, P. A. Tambyah, W. P. Goh, V. H. Tam, and D. A. Fisher. 2008. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J. Antimicrob. Chemother. 62:168-171.
13. Kitzis, M. D., and F. W. Goldstein. 2006. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin. Microbiol. Infect. 12:92-95. (Pubitemid 43372248)
14. Lodise, T. P., J. Graves, A. Evans, E. Graffunder, M. Helmecke, B. M. Lomaestro, and K. Stellrecht. 2008. Relationship between vancomycin MIC and failure among patients with MRSA bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
15. Lodise, T. P., B. Lomaestro, J. Graves, and G. L. Drusano. 2008. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52:1330-1336.
16. Lowdin, E., I. Odenholt, and O. Cars. 1998. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. 42:2739-2744.
17. Matzke, G. R., G. G. Zhanel, and D. R. Guay. 1986. Clinical pharmacokinetics of vancomycin. Clin. Pharmacokinet. 11:257-282. (Pubitemid 16050520)
18. Mohr, J. F., and B. E. Murray. 2007. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 44:1536-1542. (Pubitemid 46871498)
19. Moise, P. A., G. Sakoulas, A. Forrest, and J. J. Schentag. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:2582-2586.
20. Moise-Broder, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942.
21. Pea, F., M. Bertolissi, A. Di Silvestre, D. Poz, F. Giordano, and M. Furlanut. 2002. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int. J. Antimicrob. Agents 20:326-332. (Pubitemid 35300428)
22. Pea, F., D. Poz, M. Baraldo, and M. Furlanut. 2000. Optimisation of vancomycin regimen in neutropenic haematological patients with normal renal function: multiple daily doses may be preferable. Clin. Drug Investig. 19:213-218. (Pubitemid 30166914)
23. Pea, F., and P. Viale. 2007. Pharmacodynamics of antibiotics to treat multidrug- resistant gram-positive hospital infections. Expert Rev. Anti-Infect. Ther. 5:255-270. (Pubitemid 46681744)
24. Pea, F., and P. Viale. 2008. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin. Pharmacokinet. 47:147-152.
25. Pea, F., P. Viale, and M. Furlanut. 2005. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin. Pharmacokinet. 44:1009-1034. (Pubitemid 41356389)
26. Plan, O., G. Cambonie, E. Barbotte, P. Meyer, C. Devine, C. Milesi, O. Pidoux, M. Badr, and J. C. Picaud. 2008. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented gram-positive infections: a new dosage schedule. Arch. Dis. Child Fetal Neonatal Ed. 93:F418-F421.
27. Porath, A. D., and G. D. Brooks. 2008. Vancomycin minimum inhibitory concentration as a predictor of mortality in methicillin-resistant Staphylococcus aureus bacteremia: a second look. Clin. Infect. Dis. 46:1483-1484.
28. Rello, J., J. Sole-Violan, M. Sa-Borges, J. Garnacho-Montero, E. Munoz, G. Sirgo, M. Olona, and E. Diaz. 2005. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit. Care Med. 33:1983-1987.
29. Roberts, J. A., J. Lipman, S. Blot, and J. Rello. 2008. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr. Opin. Crit. Care 14:390-396.
30. Rybak, M. J. 2006. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42(Suppl. 1):S35-S39. (Pubitemid 41832063)
31. Sakoulas, G., H. S. Gold, R. A. Cohen, L. Venkataraman, R. C. Moellering, and G. M. Eliopoulos. 2006. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J. Antimicrob. Chemother. 57:699-704.
32. Scheetz, M. H., R. G. Wunderink, M. J. Postelnick, and G. A. Noskin. 2006. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 26:539-550.
33. Shorr, A. F., A. Combes, M. H. Kollef, and J. Chastre. 2006. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit. Care Med. 34:700-706.
34. Soriano, A., F. Marco, J. A. Martinez, E. Pisos, M. Almela, V. P. Dimova, D. Alamo, M. Ortega, J. Lopez, and J. Mensa. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
35. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin- susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794.
36. Wang, G., J. F. Hindler, K. W. Ward, and D. A. Bruckner. 2006. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44:3883-3886.
37. Wysocki, M., F. Delatour, F. Faurisson, A. Rauss, Y. Pean, B. Misset, F. Thomas, J. F. Timsit, T. Similowski, H. Mentec, L. Mier, and D. Dreyfuss. 2001. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 45:2460-2467. (Pubitemid 32801896)